ISIS-SMNRx is a new drug being developed by ISIS Pharmaceuticals with the goal of reducing the severity of spinal muscular atrophy (SMA) in infants. Classified as an antisense…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Spinal muscular atrophy (SMA) is the result of being born without – or with a defective version of – the survival motor neuron 1 (SMN1) gene. This gene…
